Cover Image
市場調查報告書

胰臟癌:開發中產品分析

Pancreatic Cancer - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 200987
出版日期 內容資訊 英文 2092 Pages
訂單完成後即時交付
價格
Back to Top
胰臟癌:開發中產品分析 Pancreatic Cancer - Pipeline Review, H1 2017
出版日期: 2017年06月30日 內容資訊: 英文 2092 Pages
簡介

所謂胰臟癌 ,是胰臟組織產生惡性細胞(癌症細胞)這樣的疾病,又稱外分泌系統癌症。主要的前兆、症狀,是腹上部痛與擴散到背部、黃疸、食慾不振、體重減少、憂鬱症、血塊等。在主要的易罹病素質上有年齡和性別、抽煙、糖尿病、家族病史等。主要的治療方法中,包含外科手術、化療、放射治療等。

本報告提供全球各國的胰臟癌治療用的開發中產品的開發情形相關分析著開發中產品的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查。

簡介

胰臟癌概要

治療藥的開發

胰臟癌:企業開發中的治療藥

胰臟癌:大學/機關研究中的治療藥

胰臟癌:開發中產品概況

胰臟癌:企業開發中的產品

胰臟癌:大學/機關研究中的產品

胰臟癌的治療藥開發企業

胰臟癌:治療藥的評估

藥物簡介

胰臟癌:暫停中的計劃

胰臟癌:開發中止的產品

胰臟癌:產品開發的里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9473IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer - Pipeline Review, H1 2017, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape.

Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice), loss of appetite, weight loss, depression and blood clots. Predisposing factors include age, gender, smoking, diabetes and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pancreatic Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pancreatic Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pancreatic Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pancreatic Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 16, 120, 121, 2, 8, 273, 36 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 20, 9, 52 and 6 molecules, respectively.

Pancreatic Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatic Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Pancreatic Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pancreatic Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pancreatic Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatic Cancer (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pancreatic Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pancreatic Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Pancreatic Cancer - Overview
  • Pancreatic Cancer - Therapeutics Development
  • Pancreatic Cancer - Therapeutics Assessment
  • Pancreatic Cancer - Companies Involved in Therapeutics Development
  • Pancreatic Cancer - Drug Profiles
  • Pancreatic Cancer - Dormant Projects
  • Pancreatic Cancer - Discontinued Products
  • Pancreatic Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Pancreatic Cancer, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..12), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..13), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..14), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..15), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..16), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..17), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..18), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..19), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..20), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..10), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..11), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..12), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..13), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..14), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..15), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..16), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..17), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..18), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..19), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..20), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..21), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..22), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..23), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..24), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..25), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..26), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..27), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..28), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..29), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..30), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..31), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..8), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..9), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..10), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..11), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..12), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..13), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..14), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..15), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..9), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..10), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..11), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..12), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..13), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..14), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pancreatic Cancer - Pipeline by 3-V Biosciences Inc, H1 2017
  • Pancreatic Cancer - Pipeline by 4P-Pharma SAS, H1 2017
  • Pancreatic Cancer - Pipeline by AB Science SA, H1 2017
  • Pancreatic Cancer - Pipeline by AbbVie Inc, H1 2017
  • Pancreatic Cancer - Pipeline by AbGenomics International Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Ability Pharmaceuticals SL, H1 2017
  • Pancreatic Cancer - Pipeline by Actuate Therapeutics Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Adamed Sp z oo, H1 2017
  • Pancreatic Cancer - Pipeline by Aduro BioTech Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Advanced Cancer Therapeutics LLC, H1 2017
  • Pancreatic Cancer - Pipeline by Advantagene Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Agenus Inc, H1 2017
  • Pancreatic Cancer - Pipeline by AGV Discovery SAS, H1 2017
  • Pancreatic Cancer - Pipeline by AIMM Therapeutics BV, H1 2017
  • Pancreatic Cancer - Pipeline by Alissa Pharma, H1 2017
  • Pancreatic Cancer - Pipeline by Allinky Biopharma, H1 2017
  • Pancreatic Cancer - Pipeline by Almac Discovery Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Altor BioScience Corp, H1 2017
  • Pancreatic Cancer - Pipeline by Ambrx Inc, H1 2017
  • Pancreatic Cancer - Pipeline by amcure GmbH, H1 2017
  • Pancreatic Cancer - Pipeline by American Gene Technologies International Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Amgen Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Anavex Life Sciences Corp, H1 2017
  • Pancreatic Cancer - Pipeline by Andarix Pharmaceuticals Inc, H1 2017
  • Pancreatic Cancer - Pipeline by ANP Technologies Inc, H1 2017
  • Pancreatic Cancer - Pipeline by AntiCancer Inc, H1 2017
  • Pancreatic Cancer - Pipeline by APEIRON Biologics AG, H1 2017
  • Pancreatic Cancer - Pipeline by Aphios Corp, H1 2017
  • Pancreatic Cancer - Pipeline by APIM Therapeutics AS, H1 2017
  • Pancreatic Cancer - Pipeline by Apogenix GmbH, H1 2017
  • Pancreatic Cancer - Pipeline by Aposense Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by ARMO Biosciences Inc, H1 2017
  • Pancreatic Cancer - Pipeline by ArQule Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Array BioPharma Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Astellas Pharma Inc, H1 2017
  • Pancreatic Cancer - Pipeline by AstraZeneca Plc, H1 2017
  • Pancreatic Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Autotelic Inc, H1 2017
  • Pancreatic Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Axcentua Pharmaceuticals AB, H1 2017
  • Pancreatic Cancer - Pipeline by Basilea Pharmaceutica Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Bavarian Nordic A/S, H1 2017
  • Pancreatic Cancer - Pipeline by Bayer AG, H1 2017
  • Pancreatic Cancer - Pipeline by BeiGene (Beijing) Co Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Bellicum Pharmaceuticals Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Berg LLC, H1 2017
  • Pancreatic Cancer - Pipeline by BerGenBio ASA, H1 2017
  • Pancreatic Cancer - Pipeline by Beta Pharma Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Bexion Pharmaceuticals LLC, H1 2017
  • Pancreatic Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Bio-Path Holdings Inc, H1 2017
  • Pancreatic Cancer - Pipeline by BioLineRx Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Biomar Microbial Technologies, H1 2017
  • Pancreatic Cancer - Pipeline by Biomunex Pharmaceuticals, H1 2017
  • Pancreatic Cancer - Pipeline by Bioncotech Therapeutics SL, H1 2017
  • Pancreatic Cancer - Pipeline by Bionomics Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by BioNTech AG, H1 2017
  • Pancreatic Cancer - Pipeline by Biotest AG, H1 2017
  • Pancreatic Cancer - Pipeline by Biouniversa srl, H1 2017
  • Pancreatic Cancer - Pipeline by BLR Bio LLC, H1 2017
  • Pancreatic Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Pancreatic Cancer - Pipeline by Boston Biomedical Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Pancreatic Cancer - Pipeline by Cadila Pharmaceuticals Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Calithera Biosciences Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Cancer Prevention Pharmaceuticals Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Cantargia AB, H1 2017
  • Pancreatic Cancer - Pipeline by Cascadian Therapeutics Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Cavion LLC, H1 2017
  • Pancreatic Cancer - Pipeline by CBT Pharmaceuticals Inc, H1 2017
  • Pancreatic Cancer - Pipeline by CCRP Therapeutics GmbH, H1 2017
  • Pancreatic Cancer - Pipeline by Celgene Corp, H1 2017
  • Pancreatic Cancer - Pipeline by Celleron Therapeutics Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Cellular Biomedicine Group Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Celprogen Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Celyad SA, H1 2017
  • Pancreatic Cancer - Pipeline by Centrose LLC, H1 2017
  • Pancreatic Cancer - Pipeline by Ceronco Biosciences, H1 2017
  • Pancreatic Cancer - Pipeline by ChemoCentryx Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Clovis Oncology Inc, H1 2017
  • Pancreatic Cancer - Pipeline by COARE Biotechnology Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Codiak BioSciences Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Concordia International Corp, H1 2017
  • Pancreatic Cancer - Pipeline by Confluence Life Sciences Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Critical Outcome Technologies Inc, H1 2017
  • Pancreatic Cancer - Pipeline by CrystalGenomics Inc, H1 2017
  • Pancreatic Cancer - Pipeline by CTI BioPharma Corp, H1 2017
  • Pancreatic Cancer - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017
  • Pancreatic Cancer - Pipeline by CytomX Therapeutics Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Cytori Therapeutics Inc, H1 2017
  • Pancreatic Cancer - Pipeline by CytRx Corp, H1 2017
  • Pancreatic Cancer - Pipeline by CyTuVax BV, H1 2017
  • Pancreatic Cancer - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by DEKK-TEC Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Denceptor Therapeutics Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Diffusion Pharmaceuticals Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Eisai Co Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Eleison Pharmaceuticals LLC, H1 2017
  • Pancreatic Cancer - Pipeline by Eli Lilly and Company, H1 2017
  • Pancreatic Cancer - Pipeline by Endor Nanotechnologies SL, H1 2017
  • Pancreatic Cancer - Pipeline by Ensemble Therapeutics Corp, H1 2017
  • Pancreatic Cancer - Pipeline by Ensol Biosciences Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Erytech Pharma SA, H1 2017
  • Pancreatic Cancer - Pipeline by Esperance Pharmaceuticals Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Etubics Corp, H1 2017
  • Pancreatic Cancer - Pipeline by Exelixis Inc, H1 2017
  • Pancreatic Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Faron Pharmaceuticals Oy, H1 2017
  • Pancreatic Cancer - Pipeline by FibroGen Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Formosa Laboratories Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Forty Seven Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Fountain Biopharma Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Fujifilm Corp, H1 2017
  • Pancreatic Cancer - Pipeline by Fusion Antibodies Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Galena Biopharma Inc, H1 2017
  • Pancreatic Cancer - Pipeline by GamaMabs Pharma SA, H1 2017
  • Pancreatic Cancer - Pipeline by Geistlich Pharma AG, H1 2017
  • Pancreatic Cancer - Pipeline by Genelux Corp, H1 2017
  • Pancreatic Cancer - Pipeline by Genentech Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Genisphere LLC, H1 2017
  • Pancreatic Cancer - Pipeline by Genmab A/S, H1 2017
  • Pancreatic Cancer - Pipeline by Gilead Sciences Inc, H1 2017
  • Pancreatic Cancer - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Pancreatic Cancer - Pipeline by Globeimmune Inc, H1 2017
  • Pancreatic Cancer - Pipeline by GlycoMimetics Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Glycotope GmbH, H1 2017
  • Pancreatic Cancer - Pipeline by Golden Biotechnology Corp, H1 2017
  • Pancreatic Cancer - Pipeline by GW Pharmaceuticals Plc, H1 2017
  • Pancreatic Cancer - Pipeline by Halozyme Therapeutics Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Helix BioPharma Corp, H1 2017
  • Pancreatic Cancer - Pipeline by Horizon Pharma Plc, H1 2017
  • Pancreatic Cancer - Pipeline by Humorigin Biotechnology Corp, H1 2017
  • Pancreatic Cancer - Pipeline by iCeutica Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Idera Pharmaceuticals Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Igenica Biotherapeutics Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Ignyta Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Immodulon Therapeutics Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Immune Pharmaceuticals Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Immune System Key Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Immune Therapeutics Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Immunitor Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Immunomedics Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Immunotope Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Immunovo BV, H1 2017
  • Pancreatic Cancer - Pipeline by Immupharma Plc, H1 2017
  • Pancreatic Cancer - Pipeline by Incyte Corp, H1 2017
  • Pancreatic Cancer - Pipeline by Inflection Biosciences Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Innopharmax Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Innovation Pharmaceuticals Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
  • Pancreatic Cancer - Pipeline by InteRNA Technologies BV, H1 2017
  • Pancreatic Cancer - Pipeline by Intezyne Technologies Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Inventiva, H1 2017
  • Pancreatic Cancer - Pipeline by InvivoGen Therapeutics, H1 2017
  • Pancreatic Cancer - Pipeline by Io Therapeutics Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Ipsen SA, H1 2017
  • Pancreatic Cancer - Pipeline by ISU ABXIS Co Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Jasco Pharmaceuticals LLC, H1 2017
  • Pancreatic Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Johnson & Johnson, H1 2017
  • Pancreatic Cancer - Pipeline by Juno Therapeutics Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Kalyra Pharmaceuticals Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Kancera AB, H1 2017
  • Pancreatic Cancer - Pipeline by Karcinolys SAS, H1 2017
  • Pancreatic Cancer - Pipeline by Karyopharm Therapeutics Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Keystone Nano Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Komipharm International Co Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Kura Oncology Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Lead Discovery Center GmbH, H1 2017
  • Pancreatic Cancer - Pipeline by Lidds AB, H1 2017
  • Pancreatic Cancer - Pipeline by Lion Biotechnologies Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Lipopharma Therapeutics SL, H1 2017
  • Pancreatic Cancer - Pipeline by Lixte Biotechnology Holdings Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Loxo Oncology Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Lymphocyte Activation Technologies SA, H1 2017
  • Pancreatic Cancer - Pipeline by MabVax Therapeutics Holdings Inc, H1 2017
  • Pancreatic Cancer - Pipeline by MacroGenics Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Mateon Therapeutics Inc, H1 2017
  • Pancreatic Cancer - Pipeline by MaxiVAX SA, H1 2017
  • Pancreatic Cancer - Pipeline by Meabco A/S, H1 2017
  • Pancreatic Cancer - Pipeline by Mebiopharm Co Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by MediaPharma Srl, H1 2017
  • Pancreatic Cancer - Pipeline by Medicenna Therapeutics Corp, H1 2017
  • Pancreatic Cancer - Pipeline by MedImmune LLC, H1 2017
  • Pancreatic Cancer - Pipeline by Medivir AB, H1 2017
  • Pancreatic Cancer - Pipeline by Merck & Co Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Merck KGaA, H1 2017
  • Pancreatic Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Merus NV, H1 2017
  • Pancreatic Cancer - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Moleculin Biotech Inc, H1 2017
  • Pancreatic Cancer - Pipeline by MolMed SpA, H1 2017
  • Pancreatic Cancer - Pipeline by Monopar Therapeutics LLC, H1 2017
  • Pancreatic Cancer - Pipeline by Morphotek Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Mount Tam Biotechnologies Inc, H1 2017
  • Pancreatic Cancer - Pipeline by NanoCarrier Co Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by NantKwest Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Nascent Biotech Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Natco Pharma Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by NatureWise Biotech & Medicals Corp, H1 2017
  • Pancreatic Cancer - Pipeline by NBE-Therapeutics AG, H1 2017
  • Pancreatic Cancer - Pipeline by Nerviano Medical Sciences Srl, H1 2017
  • Pancreatic Cancer - Pipeline by NewLink Genetics Corp, H1 2017
  • Pancreatic Cancer - Pipeline by NormOxys Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Northwest Biotherapeutics Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Novartis AG, H1 2017
  • Pancreatic Cancer - Pipeline by Novogen Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Novus Therapeutics Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Noxxon Pharma AG, H1 2017
  • Pancreatic Cancer - Pipeline by NuCana BioMed Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by OBI Pharma Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Omeros Corp, H1 2017
  • Pancreatic Cancer - Pipeline by Oncodesign SA, H1 2017
  • Pancreatic Cancer - Pipeline by Oncolytics Biotech Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Oncomatryx Biopharma SL, H1 2017
  • Pancreatic Cancer - Pipeline by OncoMed Pharmaceuticals Inc, H1 2017
  • Pancreatic Cancer - Pipeline by OncoTherapy Science Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Oncovir Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Onxeo SA, H1 2017
  • Pancreatic Cancer - Pipeline by Opsona Therapeutics Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Optimum Therapeutics LLC, H1 2017
  • Pancreatic Cancer - Pipeline by Orega Biotech SAS, H1 2017
  • Pancreatic Cancer - Pipeline by Oribase Pharma, H1 2017
  • Pancreatic Cancer - Pipeline by Oryx GmbH & Co KG, H1 2017
  • Pancreatic Cancer - Pipeline by Patrys Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Pfizer Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Pharma Two B Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by PharmAbcine Inc, H1 2017
  • Pancreatic Cancer - Pipeline by PharmaCyte Biotech Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Pharmedartis GmbH, H1 2017
  • Pancreatic Cancer - Pipeline by Phoenix Biotechnology Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Plexxikon Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Polaris Pharmaceuticals Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Precision Biologics Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Prima BioMed Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Propanac Biopharma Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Provectus Biopharmaceuticals Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Puretech Health plc, H1 2017
  • Pancreatic Cancer - Pipeline by Quest PharmaTech Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Quimatryx SL, H1 2017
  • Pancreatic Cancer - Pipeline by Quintessence Biosciences Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Rafael Pharmaceuticals Inc, H1 2017
  • Pancreatic Cancer - Pipeline by RedHill Biopharma Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Redx Pharma Plc, H1 2017
  • Pancreatic Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Rhizen Pharmaceuticals SA, H1 2017
  • Pancreatic Cancer - Pipeline by Samumed LLC, H1 2017
  • Pancreatic Cancer - Pipeline by Samyang Holdings Corp, H1 2017
  • Pancreatic Cancer - Pipeline by Sanofi, H1 2017
  • Pancreatic Cancer - Pipeline by Sareum Holdings Plc, H1 2017
  • Pancreatic Cancer - Pipeline by SATT North SAS, H1 2017
  • Pancreatic Cancer - Pipeline by Selecta Biosciences Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Sierra Oncology Inc, H1 2017
  • Pancreatic Cancer - Pipeline by SignPath Pharma Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Sillajen Biotherapeutics, H1 2017
  • Pancreatic Cancer - Pipeline by Soricimed Biopharma Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Sorrento Therapeutics Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Spring Bank Pharmaceuticals Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Stelic Institute & Co Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Strongbridge Biopharma plc, H1 2017
  • Pancreatic Cancer - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Sun BioPharma Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Sunshine Biopharma Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Swedish Orphan Biovitrum AB, H1 2017
  • Pancreatic Cancer - Pipeline by Symic Biomedical Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Symphogen A/S, H1 2017
  • Pancreatic Cancer - Pipeline by SynCore Biotechnology Co Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Synergys Biotherapeutics Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Synovo GmbH, H1 2017
  • Pancreatic Cancer - Pipeline by SyntheX Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Taiwan Liposome Company Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Takara Bio Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Takis Srl, H1 2017
  • Pancreatic Cancer - Pipeline by Targovax ASA, H1 2017
  • Pancreatic Cancer - Pipeline by Tarveda Therapeutics Inc, H1 2017
  • Pancreatic Cancer - Pipeline by tella Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Threshold Pharmaceuticals Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Tiltan Pharma Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Tocagen Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Tolero Pharmaceuticals Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Transcriptogen Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Transgene SA, H1 2017
  • Pancreatic Cancer - Pipeline by TVAX Biomedical Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Tyg Oncology Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Tyme Technologies Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Tyrogenex Inc, H1 2017
  • Pancreatic Cancer - Pipeline by UbiVac LLC, H1 2017
  • Pancreatic Cancer - Pipeline by ValiRx Plc, H1 2017
  • Pancreatic Cancer - Pipeline by VasGene Therapeutics Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Vault Pharma Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Vaxeal Holding SA, H1 2017
  • Pancreatic Cancer - Pipeline by Vaximm AG, H1 2017
  • Pancreatic Cancer - Pipeline by Vaxon Biotech, H1 2017
  • Pancreatic Cancer - Pipeline by VCN Biosciences SL, H1 2017
  • Pancreatic Cancer - Pipeline by Vect-Horus SAS, H1 2017
  • Pancreatic Cancer - Pipeline by Verastem Inc, H1 2017
  • Pancreatic Cancer - Pipeline by VG Life Sciences Inc, H1 2017
  • Pancreatic Cancer - Pipeline by Vicus Therapeutics LLC, H1 2017
  • Pancreatic Cancer - Pipeline by ViiV Healthcare Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Viralytics Ltd, H1 2017
  • Pancreatic Cancer - Pipeline by Virobay Inc, H1 2017
  • Pancreatic Cancer - Pipeline by ViroStatics srl, H1 2017
  • Pancreatic Cancer - Pipeline by Wilex AG, H1 2017
  • Pancreatic Cancer - Pipeline by Zeria Pharmaceutical Co Ltd, H1 2017
  • Pancreatic Cancer - Dormant Projects, H1 2017
  • Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..6), H1 2017
  • Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..7), H1 2017
  • Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..8), H1 2017
  • Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..9), H1 2017
  • Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..10), H1 2017
  • Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..11), H1 2017
  • Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..12), H1 2017
  • Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..13), H1 2017
  • Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..14), H1 2017
  • Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..15), H1 2017
  • Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..16), H1 2017
  • Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..17), H1 2017
  • Pancreatic Cancer - Dormant Projects, H1 2017 (Contd..18), H1 2017
  • Pancreatic Cancer - Discontinued Products, H1 2017
  • Pancreatic Cancer - Discontinued Products, H1 2017 (Contd..1), H1 2017
  • Pancreatic Cancer - Discontinued Products, H1 2017 (Contd..2), H1 2017
  • Pancreatic Cancer - Discontinued Products, H1 2017 (Contd..3), H1 2017
  • Pancreatic Cancer - Discontinued Products, H1 2017 (Contd..4), H1 2017

List of Figures

  • Number of Products under Development for Pancreatic Cancer, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top